Lapatinib plus capecitabine

DRUG3 trials

Sponsors

National Center for Tumor Diseases, Heidelberg, GlaxoSmithKline, Jiangsu HengRui Medicine Co., Ltd.

Conditions

GastroEsophageal CancerHER2 Positive Metastatic Breast CancerNeoplasms, Breast

Phase 2

Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer

TerminatedNCT01145404

National Center for Tumor Diseases, HeidelbergGastroEsophageal Cancer

Start: 2010-06-30End: 2013-10-31Target: 76Updated: 2014-07-02

Phase 3

Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)

Jiangsu HengRui Medicine Co., Ltd.HER2 Positive Metastatic Breast Cancer

Start: 2017-05-03End: 2021-03-31Target: 240Updated: 2020-06-18

Unknown Phase

Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Patients

CompletedNCT01782651

GlaxoSmithKlineNeoplasms, Breast

Start: 2014-08-31End: 2015-07-31Updated: 2015-08-10

Related Papers

Cost-effectiveness analysis of the treatment pathway after trastuzumab treatment failure in patients with HER2-positive advanced breast cancer: a chinese health system perspective.

2026-05-18

Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage

Current Oncology2022-08-238 citations

Pyrotinib monotherapy or pyrotinib in combination with capecitabine could significantly prolong progression-free survival and overall survival in patients with HER2-positive metastatic breast cancer.

Journal of Clinical Oncology2022-06-012 citations

Abstract GS3-02: Updated overall survival (OS) results from the phase 3 PHOEBE trial of pyrotinib versus lapatinib in combination with capecitabine in patients with HER2-positive metastatic breast cancer

Cancer Research2022-02-1512 citations

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.

2021-02-11314 citations

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.

Journal of Clinical Oncology2020-05-2028 citations

Pyrotinib combined with capecitabine as first-line therapy for HER2-positive metastatic breast cancer: A pooled analysis of three randomized controlled trials.

Journal of Clinical Oncology2020-05-201 citations

Pyrotinib plus capecitabine for HER2-positive, trastuzumab-resistant metastatic breast cancer: A pooled analysis of three randomized controlled trials.

Journal of Clinical Oncology2020-05-20

Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.

2015-02-1642 citations

Lapatinib versus lapatinib plus capecitabine as second-line treatment in HER-2-overexpressing metastatic gastro-esophageal cancer (GC): A randomized phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Journal of Clinical Oncology2015-01-201 citations